Therapy-related myelodysplastic syndrome with monosomy 5 and 7 following successful therapy for acute promyelocytic leukemia with anthracyclines.

Abstract

Myelodysplastic syndrome (MDS) in patients treated for acute promyelocytic leukemia (APL) is a rare event. We describe a patient with APL who developed MDS 40 months after entering complete remission (CR). Karyotypic analysis revealed monosomy 5 and 7, which are cytogenetic changes usually occurring after the use of alkylating agents. The patient had received only anthracyclines as potential leukemogenic drugs. A review of the literature on t-AML/MDS occurring after successful therapy for APL showed three similar cases. These observations suggest that anthracyclines may cause t-AML/MDS similar to that induced by alkylating agents.

• Authors: A Athanasiadou, R Saloum, I Zorbas, A Tsompanakou, I Batsis, A Fassas, A Anagnostopoulos
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 43 Issue 12 Pg. 2409-11 (Dec 2002) ISSN: 1042-8194 [Print] United States
• PMID: 12613533 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Antibiotics, Antineoplastic

Topics

• Antibiotics, Antineoplastic (adverse effects, therapeutic use)
• Chromosomes, Human, Pair 5
• Chromosomes, Human, Pair 7
• Fatal Outcome
• Female
• Graft vs Host Disease (drug therapy)
• Humans
• Immunosuppression Therapy
• Leukemia, Myeloid, Acute (etiology)
• Leukemia, Promyelocytic, Acute (drug therapy, therapy)
• Middle Aged
• Monosomy
• Myelodysplastic Syndromes (chemically induced, genetics, pathology)
• Neoplasms, Second Primary (chemically induced, genetics, pathology)
• Peripheral Blood Stem Cell Transplantation (adverse effects)
• Transplantation, Homologous